logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
E

Elisa Fontana

Sarah Cannon Research Institute
H指数:20
被引数:1,874

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial

Werner解旋酶抑制剂用于高级别微卫星不稳定性实体瘤：一项1期临床试验

Nature Medicine
IF50
2026-09-290
OA
Timothy A. Yap; Elisa Fontana; Natalie Cook; Marwan Fakih; Oliver Bechter; Erica S. Tsang; Emiliano Calvo; Kristoffer S. Rohrberg; Javier Ros; Ignacio Matos; John H. Strickler; Malaka Ameratunga; Meredith Pelster; Adam Sharp; Jaspreet Grewal; Susanna Ulahannan; Rajesh Belani; Matthew P. Patricelli; Sophia M. Blake; David Dejardin; Stephen Fowler; Christina Godfried Sie; Astrid Heller; Nina Henkel; Michael Hettich; Angelika Lahr; David Lamparter; Charlotte Lane; Ting Liu; Hélène Meistermann; Christophe Meille; Neil Parrott; Sotirios K. Sotiriou; Denise Reeves; Barbara Romagnoli; Piergiorgio Pettazzoni; Daniel Waterkamp; Matthias Wittwer; Yali Fu; Sophie Postel-Vinay
Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: an individual patient data meta-analysis

可切除或已切除结直肠癌肝转移患者的系统性化疗：一项个体患者数据Meta分析

European Journal of Cancer
IF7.1
2025-11-010
PRE
Giacomo Bregni; Bryan Leurquin; Peggy Giasafaki; Nobuyuki Takemura; Norihiro Kokudo; Kiyoshi Hasegawa; Yutaka Matsuyama; Yujiro Nishioka; Thomas Aparicio; Rosine Guimbaud; Karine Le Malicot; Dongsheng Tu; Chris O'Callaghan; Manfred P Lutz; Elisa Fontana; Markus Moehler; Murielle E Mauer; Francesco Sclafani
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

Zanzalintinib联合atezolizumab与regorafenib对比治疗难治性结直肠癌(STELLAR-303)：一项随机、开放标签、III期临床试验

The Lancet
IF97.3
2025-10-200
PRE
J Randolph Hecht; Young Suk Park; Josep Tabernero; Myung-Ah Lee; Soohyeon Lee; Anna C Virgili; Marc Van den Eynde; Elisa Fontana; Marwan Fakih; Gholamreza Asghari; Jane So; Alexander Stein; Olivier Dubreuil; Lubomir Bodnar; Cixin Steven He; Guan Wang; Robina Smith; Cathy Eng; Anwaar Saeed
Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study

高选择性FGFR2抑制剂lirafugratinib在患有FGFR2融合或重排 (f/r) 的晚期实体瘤患者 (pts) 中的肿瘤不可知疗效和安全性: ReFocus研究

EUROPEAN JOURNAL OF CANCER
IF7.1
2024-10-010
PRE
Hollebecque, A.; Dotan, E.; Liao, C. Y. A.; Roda, D.; Fontana, E.; Babiker, H.; Kim, R. D.; Oh, D. Y.; Ghiringhelli, F.; Moreno, I.; Liu, J.; Subbiah, V.; Varkaris, A.; Borad, M. J.; Cassier, P. A.; Deary, A.; Ramirez, F. T.; Ricard, F.; Jen, K. Y.; Schram, A. M.
Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors

接受自行车毒素偶联物（BTCs）BT8009或BT5528单药治疗的晚期实体瘤患者中出现的周围神经病变（PN）。

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Doger de Speville, B.; Mckean, M.; Baldini, C.; Italiano, A.; Reig Torras, O.; Fontana, E.; Verlingue, L.; Bashir, B.; Wang, J. S.; DeMars, L.; Josephs, K.; Feliu, W. I. Ortuzar; De, A.; Gu, X.; Xu, C.; Li, M.; Carter, L.
BT8009 monotherapy in enfortumab vedotin (EV)-naive patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1

BT8009单药治疗在enfotumab vedotin（EV）初治患者(pts)中的转移性尿路上皮癌（mUC）：Duravelo-1研究的更新结果

ANNALS OF ONCOLOGY
IF65.4
2024-09-012
PRE
Reig Torras, O.; Crouzet, L.; Necchi, A.; Baldini, C.; Lostes Bardaji, M. J.; Doger de Speville, B.; Italiano, A.; Verlingue, L.; Boni, V.; Carter, L.; Duran, I.; Garmezy, B.; Galsky, M. D.; Falchook, G. S.; DeMars, L.; Josephs, K.; Xu, C.; Bader, J.; Fontana, E.
Interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors

SGN-PDL1V（PF-08046054）在PD-L1表达实体瘤患者中的I期研究中期结果

ANNALS OF ONCOLOGY
IF65.4
2024-09-012
PRE
Oliva, M.; Ochsenreither, S.; Le Tourneau, C.; Champiat, S.; Saleh, R.; Burkitt, K.; Nabell, L.; Steeghs, N.; Spreafico, A.; Minchom, A. R.; Patnaik, A.; Call, J. A.; Fontana, E.; Kotecki, N.; Garralda, E.; Zivi, A.; Riess, J. W.; Gupta, S.; Zhang, R.; Gillison, M.
PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation

PYNNACLE II期临床试验：评估rezatapopt（PC14586）在携带TP53 Y220C突变的实体瘤中的疗效

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Schram, A. M.; Lopes, G.; El-Khoueiry, A. B.; Fontana, E.; Karasic, T. B.; Kummar, S.; Lorusso, P.; Gregorc, V.; Millward, M.; Aix, S. Ponce; Richardson, D. L.; Perez, D. Roda; Spira, A. I.; Tan, D. S.; Thompson, J. A.; Uprety, D.; Fellous, M.; Qin, Y. G.; Dumbrava, E. E.
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
2024-05-062
OAAI
Fontana, Elisa; Rosen, Ezra; Lee, Elizabeth K.; Hojgaard, Martin; Mettu, Niharika B.; Lheureux, Stephanie; Carneiro, Benedito A.; Cote, Gregory M.; Carter, Louise; Plummer, Ruth; Mahalingam, Devalingam; Fretland, Adrian J.; Schonhoft, Joseph D.; Silverman, Ian M.; Wainszelbaum, Marisa; Xu, Yi; Ulanet, Danielle; Koehler, Maria; Yap, Timothy A.
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations
JNCI CANCER SPECTRUM
IF4.1
2024-04-161
OAAI
Necchi, Andrea; Ramlau, Rodryg; Falcon Gonzalez, Alejandro; Chaudhry, Arvind; Todenhoefer, Tilman; Tahbaz, Rana; Fontana, Elisa; Giannatempo, Patrizia; Deville, Jean-Laurent; Pouessel, Damien; Yoon, Shinkyo; Powles, Thomas; Bernat, Mathieu; Hackl, Manuel; Marszewska, Michalina; McKernan, Phil; Saulay, Mikael; Scaleia, Federica; Engelhardt, Marc; Loriot, Yohann; Siefker-Radtke, Arlene; De Santis, Maria
Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations: Preclinical and Phase 1b results
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-010
PRE
Rosen, Ezra; Yap, Timothy A.; Fontana, Elisa; Lee, Elizabeth K.; Mahalingam, Devalingam; Hojgaard, Martin; Mettu, Niharika B.; Cote, Gregory M.; Plummer, Ruth; Silverman, Ian M.; Schonhoft, Joseph D.; Bacque, Emeline; Fretland, Adrian J.; Gomez, Gabriela; Ulanet, Danielle; Fei, Kezhen; Yang, Julia; Koehler, Maria; Roulston, Anne; Li, Li; Zimmermann, Michel; Carneiro, Benedito A.; Lheureux, Stephanie
Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-010
PRE
Schram, Alison M.; Subbiah, Vivek; Liao, Chih-Yi (Andy); Moreno, Victor; Desamparados, Roda; Ponz-Sarvise, Mariano; Dotan, Efrat; Cassier, Philippe Alexandre; Moreno, Irene; Varkaris, Andreas; Kim, Richard D.; Garralda, Elena; Opdam, Frans; Tai, David; Italiano, Antoine; Oh, Do-Youn; Goyal, Lipika; Fontana, Elise; Liu, Jia; Boukovala, Myrto; Ghiringelli, Francois; Borad, Mitesh J.; Babiker, Hani; Jin, Zhaohui; Millward, Michael; Yachnin, Jeffrey; Kamath, Suneel Deepak; Coward, Jermaine M.; Yoo, Changhoon; Kelley, Robin Kate; Sahai, Vaibhav; Bridgewater, John; Springfield, Christoph; Florou, Vaia; El-Khoueiry, Anthony; Eskens, Ferry; Lin, Bruce; Paulson, Scott; Curigliano, Giuseppe; Murphy, Meredith; Deary, Alicia; Ricard, Fabien; Jen, Kai Yu; Ramirez, Florence (Tianhui); Blakesley, Rick E.; Schmidt-Kittler, Oleg; Mar, Brenton G.; Park, Joon Oh; Hollebecque, Antoine
Trial in progress: First-in-human phase I dose-escalation study of a novel Bicycle toxin conjugate (BT5528) targeting EphA2 in patients with advanced solid tumors
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-010
PRE
Fontana, Elisa; Bashir, Babar; Wang, Judy S.; Aljumaily, Raid; Machiels, Jean-Pascal; Vieito, Maria; Falchook, Gerald; Carter, Louise; de Speville, Bernard Doger; Greystoke, Alastair; Kim, Sang Wun; Kotecki, Nuria; Spira, Alexander I.; Candilejo, Irene Moreno; Basu, Bristi; Prenen, Hans; Bessudo, Alberto; Nagasaka, Misako; Ahnert, Jordi Rodon; Park, Joo-Hwan; Teo, Min-Yuen; Rotow, Julia; Liu, Jie; De Rienzo, Assunta; Li, Mengyao; Domingo, Adriana; Orr, Hanna; Bennett, Gavin; Sharma, Rajiv; McKean, Meredith

研究方向

暂未获取到该数据
A
Anguraj Sadanandam
H 指数:42论文数:236被引数:1.5万
T
Timothy A. Yap
H 指数:77论文数:1,361被引数:2.6万
E
Ezra Y. Rosen
H 指数:18论文数:174被引数:3,178
G
Gift Nyamundanda
H 指数:12论文数:66被引数:5,892
S
Stéphanie Lheureux
H 指数:38论文数:473被引数:7,789
E
Elizabeth Smyth
H 指数:44论文数:293被引数:1.9万
N
Niharika B. Mettu
H 指数:13论文数:141被引数:811
J
Joseph D. Schonhoft
H 指数:22论文数:123被引数:1,547
D
Danielle Ulanet
H 指数:14论文数:70被引数:1,609
G
Gerald S. Falchook
H 指数:68论文数:810被引数:2.6万